NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis $1.90 -0.02 (-0.79%) (As of 10:30 AM ET) Add Compare Share Share Today's Range$1.88▼$1.9950-Day Range$1.52▼$2.3952-Week Range$0.92▼$3.73Volume891,153 shsAverage Volume3.60 million shsMarket Capitalization$466.62 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Lexicon Pharmaceuticals alerts: Email Address Lexicon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside283.6% Upside$7.50 Price TargetShort InterestBearish9.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 18 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.70) to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.66 out of 5 starsMedical Sector679th out of 924 stocksPharmaceutical Preparations Industry312th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Lexicon Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.08% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently increased by 7.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXRX. Previous Next 2.9 News and Social Media Coverage News SentimentLexicon Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Lexicon Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest10 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat Follows4 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Lexicon Pharmaceuticals is held by insiders.Percentage Held by Institutions74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexicon Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.70) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexicon Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Read More LXRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXRX Stock News HeadlinesAugust 21 at 5:49 PM | markets.businessinsider.comBuy Rating for Lexicon Pharmaceuticals Amid Positive Regulatory and Clinical Developments for ZYNQUISTAAugust 21 at 12:47 PM | finanznachrichten.deLexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for ZynquistaAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.August 21 at 12:47 PM | markets.businessinsider.comLexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for ZynquistaAugust 21 at 12:47 PM | markets.businessinsider.comLexicon Pharma Announces FDA Advisory Committee Meeting For ZynquistaAugust 18, 2024 | finance.yahoo.comLXRX Sep 2024 1.000 put (LXRX240920P00001000)August 17, 2024 | americanbankingnews.comHC Wainwright Analysts Lower Earnings Estimates for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)August 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Turnstone Biologics Corp. (TSBX)August 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. August 16, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Lexicon Pharmaceuticals, Inc. Raised by Leerink Partnrs (NASDAQ:LXRX)August 14, 2024 | finanznachrichten.deLexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial PortfolioAugust 14, 2024 | markets.businessinsider.comOptimized Strategy and Clinical Progress Bolster Buy Rating for Lexicon PharmaceuticalsAugust 14, 2024 | benzinga.comAnalyst Scoreboard: 6 Ratings For Lexicon PharmaceuticalsAugust 14, 2024 | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Buy" Rating from HC WainwrightAugust 13, 2024 | globenewswire.comLexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial PortfolioAugust 8, 2024 | finance.yahoo.comLexicon Pharmaceuticals Insider Buyers Pleased With US$724k Return On InvestmentAugust 8, 2024 | msn.comLexicon to present data on sotagliflozin for diabetes, kidney diseaseAugust 7, 2024 | globenewswire.comEfficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education SpecialistsSee More Headlines Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today8/22/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CUSIP52887210 CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees140Year Founded1995Price Target and Rating Average Stock Price Target$7.50 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+292.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-177,120,000.00 Net Margins-5,509.34% Pretax Margin-8,376.55% Return on Equity-115.40% Return on Assets-65.19% Debt Debt-to-Equity Ratio0.35 Current Ratio15.58 Quick Ratio15.56 Sales & Book Value Annual Sales$3.64 million Price / Sales129.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book5.03Miscellaneous Outstanding Shares246,237,000Free Float229,493,000Market Cap$470.31 million OptionableOptionable Beta1.35 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Lonnel Coats (Age 59)CEO & Director Comp: $1.14MMr. Jeffrey L. Wade J.D. (Age 59)President & CFO Comp: $752.05kMr. Brian T. Crum (Age 51)Senior VP, General Counsel & Secretary Comp: $596.48kDr. Alan J. Main Ph.D. (Age 70)Executive Vice President of Innovation & Chemical Sciences Comp: $576.96kDr. Craig B. Granowitz M.D. (Age 59)Ph.D., Senior VP & Chief Medical Officer Comp: $652.48kMs. Kristen L. Alexander (Age 56)Vice President of Finance & Accounting Ms. Lisa M. DeFrancesco (Age 44)Head of Investor Relations & Corporate Strategy Mr. Dixon TerryVice President of ComplianceMs. Carrie SiragusaVice President of MarketingMs. Desiree GendronVice President of Sales & TrainingMore ExecutivesKey CompetitorsAVEO PharmaceuticalsNASDAQ:AVEOSierra OncologyNASDAQ:SRRABioCryst PharmaceuticalsNASDAQ:BCRXDynavax TechnologiesNASDAQ:DVAXMannKindNASDAQ:MNKDView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 2,304,150 shares on 8/20/2024Ownership: 0.936%Point72 Asset Management L.P.Bought 3,536,805 shares on 8/19/2024Ownership: 1.674%The Manufacturers Life Insurance Company Bought 14,411 shares on 8/15/2024Ownership: 0.020%CVI Holdings LLCBought 20,000 shares on 8/15/2024Ownership: 0.008%Great Point Partners LLCBought 30,000 shares on 8/14/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions LXRX Stock Analysis - Frequently Asked Questions How have LXRX shares performed this year? Lexicon Pharmaceuticals' stock was trading at $1.53 at the beginning of 2024. Since then, LXRX shares have increased by 27.8% and is now trading at $1.9550. View the best growth stocks for 2024 here. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.01. The biopharmaceutical company earned $1.65 million during the quarter, compared to the consensus estimate of $2.74 million. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative trailing twelve-month return on equity of 115.40%. What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO? 9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Lexicon Pharmaceuticals' major shareholders? Top institutional investors of Lexicon Pharmaceuticals include Point72 Asset Management L.P. (1.67%), Nantahala Capital Management LLC (0.94%), Pinnacle Associates Ltd. (0.70%) and Marshall Wace LLP (0.48%). Insiders that own company stock include International SCA Artal, Raymond Debbane, Lonnel Coats, Jeffrey L Wade and Wendy Mcdermott. View institutional ownership trends. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN) and Geron (GERN). This page (NASDAQ:LXRX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredThis Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the...Crypto 101 Media | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
